By Sneha S K and Sahil Pandey
Dec 31 (Reuters) - The U.S. Food and Drug Administration has declined to approve Corcept Therapeutics' drug for the treatment of a rare hormonal disorder, the company said on Wednesday.
Shares of the drugmaker were down 48% at $36.41.
The company said the FDA could not arrive at a favorable benefit-risk assessment for the hormone-blocking oral treatment, known as relacorilant, without Corcept providing additional evidence of effectiveness.
The company was seeking approval for relacorilant as a treatment for patients with hypertension secondary to hypercortisolism.
"FDA's request for additional data may require additional trials, significantly dimming Corcept's outlook in Cushings," said Truist analyst Joon Lee.
Hypercortisolism, also known as Cushing's syndrome, occurs when the body is exposed to high cortisol activity.
Corcept had submitted trial data that showed that relacorilant made improvements in a wide array of hypercortisolism's signs and symptoms.
"We will meet with the FDA as soon as possible to discuss the best path forward," said Joseph Belanoff, Corcept's CEO.
Main symptoms of hypercortisolism include a fatty hump between the shoulders, a rounded face, and pink or purple stretch marks on the skin. People with Cushing's also experience diabetes, high blood pressure, muscle weakness and immune suppression.
Relacorilant is a selective cortisol modulator designed to block the effects of cortisol, while avoiding certain off‑target hormonal effects.
"Given the company had opportunities to address FDA's concerns during mid and late-stage reviews, it's unclear if any further dialogue can resolve the review issues without additional trials," Lee added.
Corcept is also studying the drug in a variety of serious disorders including ovarian and prostate cancer. Its other drug known as Korlym is approved to treat high blood sugar caused by hypercortisolism in adults with endogenous Cushing's syndrome.
Other approved treatments for Cushing's syndrome include Isturisa by Recordati and Xeris Biopharma's Recorlev.
(Reporting by Sahil Pandey and Sneha S K in Bengaluru; Editing by Shailesh Kuber)
latest_posts
- 1
Astrophotographer captures rare footage of the Hubble Telescope crossing the sun (video) - 2College students are now slightly less likely to experience severe depression, research shows – but the mental health crisis is far from over
- 3Whale stranded off Germany for days found stuck again
- 4'Hero' who wrestled gun from Bondi shooter named as Ahmed al Ahmed
- 5African Forests Have Become a Source of Carbon Emissions
- 3 Italian City Cars That Outsmarted Regulations and Rivals
- The ‘Stranger Things’ finale, explained: What happens to Vecna? And why was a key character’s fate left unknown?
- Israel strikes south Lebanon after first direct talks in decades
- Go With The Breeze: Grand Paragliding Spots On the planet
- Malaysian broadcaster rejects altered graphic about electricity rate hike
- Novartis eyes more bolt-on acquisitions, CEO says
- Merz says army could be involved in mine-clearing from Hormuz
- The Extraordinary Excursion of Dental Embed Innovation
- Top 15 Supportable Design Brands Coming out on top
